Gilead Sciences, Inc. $GILD Position Increased by IFM Investors Pty Ltd

Key Points

• IFM Investors Pty Ltd increased its holdings in Gilead Sciences by 2.0% in the first quarter, owning 254,029 shares valued at approximately $28.46 million.
• Insider Johanna Mercier sold 28,000 shares for over $3.3 million, indicating a significant reduction in her personal stake of 19.70%.
• Research analysts have recently upgraded Gilead's rating, with Daiwa Capital Markets setting a price target of $128.00, suggesting positive growth expectations for the company.

IFM Investors Pty Ltd raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 254,029 shares of the biopharmaceutical company's stock after purchasing an additional 5,079 shares during the period. IFM Investors Pty Ltd's holdings in Gilead Sciences were worth $28,464,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock worth $1,541,302,000 after acquiring an additional 1,520,809 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Gilead Sciences by 15.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,234,672 shares of the biopharmaceutical company's stock worth $1,130,117,000 after acquiring an additional 1,605,730 shares during the last quarter. Finally, Royal Bank of Canada grew its position in shares of Gilead Sciences by 30.1% during the fourth quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock worth $801,655,000 after acquiring an additional 2,005,863 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

NASDAQ GILD traded down $3.31 on Friday, reaching $114.55. The company's stock had a trading volume of 6,466,956 shares, compared to its average volume of 5,830,447. Gilead Sciences, Inc. has a twelve month low of $81.57 and a twelve month high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a market cap of $142.13 billion, a PE ratio of 22.82, a PEG ratio of 0.80 and a beta of 0.36. The firm's 50 day moving average is $114.04 and its two-hundred day moving average is $110.09.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the prior year, the company earned $2.01 EPS. Gilead Sciences's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares of the company's stock, valued at approximately $67,692,231.75. This represents a 1.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,371,330 over the last 90 days. Insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on GILD. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.